BRCA2 and CDKN1A interacting proteinGenealiases: TOK-1 · TOK1
Q-omics provides the consensus-scored BCCIP profile across patient tissues and cancer cell-line models. BCCIP expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, BCCIP is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, BCCIP protein abundance shows 30,209 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, HNSC, and LSCC as cancer lineages where BCCIP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCCIP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCCIP survival associations across molecular data types. BCCIP RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCCIP RNA expression–survival associations across cancer types. High BCCIP expression shows unfavorable associations in ACC, LIHC, UVM, HNSC and LUAD, but favorable associations in LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for BCCIP RNA expression.
This table summarizes BCCIP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BCCIP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCCIP shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, LUAD and STAD. The HNSC box plot shows higher BCCIP RNA expression in tumor versus normal tissue (log2 FC = +0.859, t-test p < 0.001).
This table shows molecular features associated with BCCIP in patient tissues and cancer cell lines. In patient samples, BCCIP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCCIP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
